UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

The New England journal of medicine, 2012-11, Vol.367 (18), p.1714-1723

2012

Volltextzugriff (PDF)

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

Journal of bone and mineral research, 2011-03, Vol.26 (3), p.503-511

2011

Volltextzugriff (PDF)

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

The Lancet (British edition), 2009-04, Vol.373 (9671), p.1253-1263

2009

Volltextzugriff (PDF)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta dermato-venereologica, 2022-04, Vol.102, p.adv00698-adv00698

2022

Volltextzugriff (PDF)

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials

American journal of clinical dermatology, 2023-09, Vol.24 (5), p.821-835

2023

Volltextzugriff (PDF)

52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB60-AB60

2024

Volltextzugriff (PDF)

14190 Treatment with secukinumab of severe plaque psoriasis in pediatric patients: Study design and baseline characteristics of a double-blind study

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB133-AB133

2020

Volltextzugriff (PDF)

25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB59-AB59

2021

Volltextzugriff (PDF)

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

Paediatric drugs, 2022-07, Vol.24 (4), p.377-387

2022

Volltextzugriff (PDF)

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial

Journal of drugs in dermatology, 2016-10, Vol.15 (10), p.1226

2016

Volltextzugriff (PDF)

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Rheumatology (Oxford, England), 2013-06, Vol.52 (6), p.1058-1069

2013

Volltextzugriff (PDF)

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

Arthritis and rheumatism, 2006-05, Vol.54 (5), p.1410-1414

2006

Volltextzugriff (PDF)

Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial

Obstetrical & gynecological survey, 2009-08, Vol.64 (8), p.521-523

2009

Volltextzugriff (PDF)

The variant-specific surface protein of Giardia, VSP4A1, is a glycosylated and palmitoylated protein

Biochemical journal, 1997-02, Vol.322 ( Pt 1) (1), p.49-56

1997

Volltextzugriff (PDF)

Primary structure and biochemical properties of a variant-specific surface protein of Giardia

Molecular and biochemical parasitology, 1997-05, Vol.86 (1), p.13-27

1997

Volltextzugriff (PDF)

Poster 43: Effect of Intravenous Zoledronic Acid on Lumbar Spine Bone Mineral Density Compared to Oral Risedronate in Subgroups of Patients Receiving Glucocorticoid Therapy

PM & R, 2009-09, Vol.1 (9), p.S121-S122

2009

Volltextzugriff (PDF)

Poster 42: Effect of a Single Intravenous Infusion of Zoledronic Acid on Bone Turnover Markers Compared to Oral Risedronate Over 1 Year in Patients with Glucocorticoid-Induced Osteoporosis

PM & R, 2009-09, Vol.1 (9), p.S121-S121

2009

Volltextzugriff (PDF)

The Release of the Variant Surface Protein of Giardia to Its Soluble Isoform Is Mediated by the Selective Cleavage of the Conserved Carboxy-Terminal Domain

Biochemistry (Easton), 1996-08, Vol.35 (31), p.10143-10148

1996

Volltextzugriff (PDF)

Primary structure and biochemical properties of a variant-specific surface protein of Giardia1Note: The nucleotide sequence information reported in this paper has been submitted to the EMBL Data Library with the accession No. Z83743.1

Molecular and biochemical parasitology, 1997-05, Vol.86 (1), p.13-27

1997

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)
Japanisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials

52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

14190 Treatment with secukinumab of severe plaque psoriasis in pediatric patients: Study design and baseline characteristics of a double-blind study

25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial

The variant-specific surface protein of Giardia, VSP4A1, is a glycosylated and palmitoylated protein

Primary structure and biochemical properties of a variant-specific surface protein of Giardia

Poster 43: Effect of Intravenous Zoledronic Acid on Lumbar Spine Bone Mineral Density Compared to Oral Risedronate in Subgroups of Patients Receiving Glucocorticoid Therapy

Poster 42: Effect of a Single Intravenous Infusion of Zoledronic Acid on Bone Turnover Markers Compared to Oral Risedronate Over 1 Year in Patients with Glucocorticoid-Induced Osteoporosis

The Release of the Variant Surface Protein of Giardia to Its Soluble Isoform Is Mediated by the Selective Cleavage of the Conserved Carboxy-Terminal Domain

Primary structure and biochemical properties of a variant-specific surface protein of Giardia1Note: The nucleotide sequence information reported in this paper has been submitted to the EMBL Data Library with the accession No. Z83743.1

Suchergebnisse filtern